APA (7th ed.) Citation

DM, L., AS, R., G, L., GW, D., A, L., R, C., . . . MR, G. (2015). Cytogenetic prioritization with inclusion of molecular markers predicts outcome in previously untreated patients with chronic lymphocytic leukemia treated with fludarabine or fludarabine plus cyclophosphamide: A long-term follow-up study of the US intergroup phase III trial E2997. Leukemia & lymphoma, 56(11), 3031. https://doi.org/10.3109/10428194.2015.1023800

Chicago Style (17th ed.) Citation

DM, Lucas, et al. "Cytogenetic Prioritization with Inclusion of Molecular Markers Predicts Outcome in Previously Untreated Patients with Chronic Lymphocytic Leukemia Treated with Fludarabine or Fludarabine Plus Cyclophosphamide: A Long-term Follow-up Study of the US Intergroup Phase III Trial E2997." Leukemia & Lymphoma 56, no. 11 (2015): 3031. https://doi.org/10.3109/10428194.2015.1023800.

MLA (9th ed.) Citation

DM, Lucas, et al. "Cytogenetic Prioritization with Inclusion of Molecular Markers Predicts Outcome in Previously Untreated Patients with Chronic Lymphocytic Leukemia Treated with Fludarabine or Fludarabine Plus Cyclophosphamide: A Long-term Follow-up Study of the US Intergroup Phase III Trial E2997." Leukemia & Lymphoma, vol. 56, no. 11, 2015, p. 3031, https://doi.org/10.3109/10428194.2015.1023800.